16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
18:21 , May 25, 2018 |  BC Week In Review  |  Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor (KPT-8602)...
22:16 , May 24, 2018 |  BC Extra  |  Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
21:11 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

Toroids disable TORC

A Nature study from a University of Geneva team has shown that the yeast homolog of mTORC1 forms large aggregates that block the complex’s catalytic site, highlighting an approach for specific inhibition of the complex...
18:10 , Oct 6, 2017 |  BC Week In Review  |  Financial News

KSQ debuts with $76M financing

On Oct. 2, CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and...
11:05 , Oct 2, 2017 |  BC Extra  |  Financial News

KSQ debuts with $76M funding

CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and Alexandria Equities. The...
17:17 , Aug 18, 2017 |  BioCentury  |  Finance

Ante Antengene

With a track record of bringing drugs to market in China, the founder of Chinese in-licensing play Antengene Corp. convinced Qiming Venture Partners to lead its $21 million series A round. Antengene closed the round...
16:27 , Aug 18, 2017 |  BC Week In Review  |  Financial News

Antengene raises $21M series A

Antengene Corp. (Shanghai, China) raised $21 million on Aug. 16 in a series A round led by Qiming Venture Partners with participation by TF Capital, HG Capital and Tigermed Investment. Antengene has exclusive rights to ATG-008...
22:34 , Aug 16, 2017 |  BC Extra  |  Financial News

Antengene raises $21M series A

Antengene Corp. (Shanghai, China) raised $21 million in a series A round led by Qiming Venture Partners with participation by TF Capital, HG Capital and Tigermed Investment. Antengene has exclusive rights to ATG-008 (CC-223), an...
20:11 , Jul 27, 2017 |  BC Extra  |  Preclinical News

Group identifies S6K1 as potential target for CNS injury

In a paper published in the Journal of Neuroscience, researchers at the University of Miami Miller School of Medicine and colleagues showed that targeting ribosomal protein S6 kinase 70kDa polypeptide 1 (RPS6KB1; S6K1) could help...